The Pharmaceutical segment’s broad portfolio targets unmet medical needs across several therapeutic areas, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, irritable bowel disease and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).

  • Xian Janssen Pharmaceutical Ltd.

    Founded in 1985, Xian Janssen Pharmaceutical Ltd. is one of China’s largest pharmaceutical joint ventures. It is also one of the earliest multinational pharmaceutical companies to enter China after China’s Economic Reform. Over the past 30 years, the company has steadily developed to become the leading pharmaceutical company in China.